AAP Updates Childhood and Adolescent Immunization Schedules

Laurie Barclay, MD


February 01, 2012

February 1, 2012 — The American Academy of Pediatrics (AAP) has issued its 2012 immunization schedules for children and adolescents, according to a policy statement published in the February issue of Pediatrics. Charts for the current immunization schedules are posted online and are openly accessible to all.

The AAP recommends that clinicians use all 3 schedules and their accompanying footnotes together, rather than as stand-alone schedules.

Changes from the 2011 schedules include the following:

  • The 0- to 6-year-old schedule clarifies the administration of hepatitis B vaccine and hepatitis B immune globulin to infants weighing less than 2000 g and to infants weighing at least 2000 g whose mother is positive for hepatitis B surface antigen. This schedule also clarifies the timing of doses subsequent to the birth dose of hepatitis B vaccine.

  • The 7- to 18-year-old schedule clarifies use of the tetanus, diphtheria, and acellular pertussis vaccine for children aged 7 through 10 years who are not fully immunized with the childhood diphtheria, tetanus, acellular pertussis vaccination series.

  • The catch-up schedule includes guidance for the use of Haemophilus influenzae type b vaccine in persons at least 5 years of age.

  • The updated influenza vaccine footnotes now clarify vaccine dosing for the 2011 to 2012 season for children aged 6 months through 8 years and lists contraindications to the use of live-attenuated influenza vaccine.

  • The 2012 recommendations now include guidance for the use of measles, mumps, and rubella vaccine in infants aged 6 through 11 months who are traveling internationally.

  • Footnotes for hepatitis A now highlight administration of the second vaccine dose 6 to 18 months after the first dose. The 0- to 6-year-old schedule now includes a new yellow and purple bar describing hepatitis A vaccine recommendations for children at least 2 years of age.

  • The 2012 schedules offer guidance regarding routine administration of a booster dose of meningococcal vaccine (MCV4) and regarding administration of MCV4 to children in whom risk for meningococcal disease is increased. In the 0- to 6-year-old schedule, the MCV4 purple bar has been extended to represent licensure of Menactra (Sanofi Pasteur; MCV4-D) for use in children as young as 9 months.

  • The updated footnotes for human papillomavirus (HPV) vaccine now include a routine recommendation to vaccinate males with Gardasil (Merck; quadrivalent HPV vaccine).

  • The updated footnotes for inactivated poliovirus vaccine now note that this vaccine is not routinely recommended for US residents who are at least 18 years of age.

Clinicians should report any clinically significant adverse events after immunization to the Vaccine Adverse Event Reporting System online at https://www.vaers.hhs.gov or by telephone at 800-822-7967.

"Statements from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that contain details of recommendations for individual vaccines, including recommendations for children with high-risk conditions, are available at www.cdc.gov/vaccines/pubs/ACIP-list.htm," write Chairperson Michael T. Brady, MD, and colleagues from the Committee on Infectious Diseases, 2011 to 2012. "Information on new vaccine releases, vaccine supplies, interim recommendations resulting from vaccine shortages, and statements on specific vaccines can be found at www.aapredbook.org/news/vaccstatus.shtml and www.cdc.gov/vaccines/pubs/ACIP-list.htm."

The authors have disclosed no relevant financial relationships.

Pediatrics. 2012;129:385-386.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.